These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29026603)

  • 1. Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study.
    Lobo B; Ramos L; Martínez C; Guilarte M; González-Castro AM; Alonso-Cotoner C; Pigrau M; de Torres I; Rodiño-Janeiro BK; Salvo-Romero E; Fortea M; Pardo-Camacho C; Guagnozzi D; Azpiroz F; Santos J; Vicario M
    United European Gastroenterol J; 2017 Oct; 5(6):887-897. PubMed ID: 29026603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
    Martínez C; Lobo B; Pigrau M; Ramos L; González-Castro AM; Alonso C; Guilarte M; Guilá M; de Torres I; Azpiroz F; Santos J; Vicario M
    Gut; 2013 Aug; 62(8):1160-8. PubMed ID: 22637702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Guilarte M; Vicario M; Martínez C; de Torres I; Lobo B; Pigrau M; González-Castro A; Rodiño-Janeiro BK; Salvo-Romero E; Fortea M; Pardo-Camacho C; Antolín M; Saperas E; Azpiroz F; Santos J; Alonso-Cotoner C
    Am J Gastroenterol; 2020 Dec; 115(12):2047-2059. PubMed ID: 32740086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations.
    Vicario M; González-Castro AM; Martínez C; Lobo B; Pigrau M; Guilarte M; de Torres I; Mosquera JL; Fortea M; Sevillano-Aguilera C; Salvo-Romero E; Alonso C; Rodiño-Janeiro BK; Söderholm JD; Azpiroz F; Santos J
    Gut; 2015 Sep; 64(9):1379-88. PubMed ID: 25209656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.
    Guilarte M; Santos J; de Torres I; Alonso C; Vicario M; Ramos L; Martínez C; Casellas F; Saperas E; Malagelada JR
    Gut; 2007 Feb; 56(2):203-9. PubMed ID: 17005763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome: Jejunal Barrier Alterations Underlying Clinical Manifestations.
    Pardo-Camacho C; Ganda Mall JP; Martínez C; Pigrau M; Expósito E; Albert-Bayo M; Melón-Ardanaz E; Nieto A; Rodiño-Janeiro B; Fortea M; Guagnozzi D; Rodriguez-Urrutia A; Torres I; Santos-Briones I; Azpiroz F; Lobo B; Alonso-Cotoner C; Santos J; González-Castro AM; Vicario M
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
    Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations.
    Martínez C; Vicario M; Ramos L; Lobo B; Mosquera JL; Alonso C; Sánchez A; Guilarte M; Antolín M; de Torres I; González-Castro AM; Pigrau M; Saperas E; Azpiroz F; Santos J
    Am J Gastroenterol; 2012 May; 107(5):736-46. PubMed ID: 22415197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome.
    Willot S; Gauthier C; Patey N; Faure C
    Neurogastroenterol Motil; 2012 Aug; 24(8):734-9, e347. PubMed ID: 22625872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of small bowel mucosal gene expression in patients with irritable bowel syndrome with diarrhea.
    Camilleri M; Carlson P; Valentin N; Acosta A; O'Neill J; Eckert D; Dyer R; Na J; Klee EW; Murray JA
    Am J Physiol Gastrointest Liver Physiol; 2016 Sep; 311(3):G365-76. PubMed ID: 27445342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome.
    Lee H; Park JH; Park DI; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Chae SW
    J Neurogastroenterol Motil; 2013 Apr; 19(2):244-50. PubMed ID: 23667756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
    Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
    Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW
    Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Vivinus-Nébot M; Dainese R; Anty R; Saint-Paul MC; Nano JL; Gonthier N; Marjoux S; Frin-Mathy G; Bernard G; Hébuterne X; Tran A; Theodorou V; Piche T
    Am J Gastroenterol; 2012 Jan; 107(1):75-81. PubMed ID: 21931380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS.
    Di Nardo G; Barbara G; Cucchiara S; Cremon C; Shulman RJ; Isoldi S; Zecchi L; Drago L; Oliva S; Saulle R; Barbaro MR; Stronati L
    Neurogastroenterol Motil; 2014 Feb; 26(2):196-204. PubMed ID: 24304324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.
    Park JH; Rhee PL; Kim HS; Lee JH; Kim YH; Kim JJ; Rhee JC
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):71-8. PubMed ID: 16706815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mast Cells in Irritable Bowel Syndrome: A Systematic Review.
    Krammer L; Sowa AS; Lorentz A
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):463-472. PubMed ID: 31826052
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.